Janney Montgomery Scott LLC Has $24.91 Million Position in Gilead Sciences, Inc. $GILD

Janney Montgomery Scott LLC lessened its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 5.8% in the first quarter, HoldingsChannel.com reports. The fund owned 178,714 shares of the biopharmaceutical company’s stock after selling 11,021 shares during the period. Janney Montgomery Scott LLC’s holdings in Gilead Sciences were worth $24,907,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Strategic Investment Solutions Inc. IL acquired a new stake in shares of Gilead Sciences in the 4th quarter valued at $25,000. Vermillion & White Wealth Management Group LLC increased its stake in shares of Gilead Sciences by 71.4% in the 4th quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 85 shares during the last quarter. Quattro Advisors LLC acquired a new position in shares of Gilead Sciences during the 4th quarter worth $26,000. Wealth Preservation Advisors LLC raised its holdings in shares of Gilead Sciences by 60.0% during the 4th quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 81 shares in the last quarter. Finally, Ares Financial Consulting LLC bought a new stake in shares of Gilead Sciences during the 4th quarter worth $28,000. 83.67% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $125.40, for a total transaction of $376,200.00. Following the transaction, the chief financial officer directly owned 171,646 shares of the company’s stock, valued at approximately $21,524,408.40. The trade was a 1.72% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 3,000 shares of the company’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $123.92, for a total value of $371,760.00. Following the completion of the sale, the insider owned 124,234 shares in the company, valued at $15,395,077.28. This trade represents a 2.36% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 68,000 shares of company stock valued at $8,930,150 over the last 90 days. 0.30% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several research firms recently weighed in on GILD. Morgan Stanley reduced their price objective on Gilead Sciences from $175.00 to $168.00 in a research note on Friday, May 8th. Weiss Ratings cut shares of Gilead Sciences from a “buy (b)” rating to a “buy (b-)” rating in a report on Thursday, May 28th. Jefferies Financial Group started coverage on shares of Gilead Sciences in a research note on Tuesday, March 10th. They issued a “buy” rating and a $180.00 price target on the stock. Wall Street Zen lowered shares of Gilead Sciences from a “strong-buy” rating to a “hold” rating in a report on Saturday, May 9th. Finally, The Goldman Sachs Group upped their price objective on shares of Gilead Sciences from $125.00 to $130.00 and gave the stock a “neutral” rating in a research report on Friday, April 17th. Twenty-five equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $158.41.

Gilead Sciences Stock Down 1.2%

Shares of NASDAQ GILD opened at $126.33 on Tuesday. The company has a 50 day simple moving average of $129.94 and a 200 day simple moving average of $134.42. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.97 and a quick ratio of 1.77. Gilead Sciences, Inc. has a 1 year low of $107.75 and a 1 year high of $157.29. The firm has a market cap of $156.85 billion, a PE ratio of 17.21 and a beta of 0.31.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share for the quarter, topping analysts’ consensus estimates of $1.91 by $0.12. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The firm had revenue of $6.96 billion for the quarter, compared to analyst estimates of $6.91 billion. During the same period in the previous year, the firm posted $1.81 EPS. The company’s revenue for the quarter was up 4.4% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. On average, research analysts forecast that Gilead Sciences, Inc. will post -0.8 EPS for the current year.

Gilead Sciences Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, June 29th. Investors of record on Monday, June 15th were paid a $0.82 dividend. The ex-dividend date of this dividend was Monday, June 15th. This represents a $3.28 annualized dividend and a dividend yield of 2.6%. Gilead Sciences’s payout ratio is currently 44.69%.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.